Opinion|Videos|October 6, 2023
The Role of BRAF in mCRC
Christina Wu, MB, BCh, MD, discusses BRAF V600E mutations in metastatic colorectal cancer, including the various detection methods, the different classes of BRAF mutations, and the evolution of targeting treatments.
Advertisement
Episodes in this series
Advertisement
Related to this article
More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
3
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5